<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Influenza Other Respir Viruses</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1750-2659</journal-id><journal-id journal-id-type="publisher-id">IRV</journal-id><journal-title-group><journal-title>Influenza and Other Respiratory Viruses</journal-title></journal-title-group><issn pub-type="ppub">1750-2640</issn><issn pub-type="epub">1750-2659</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7182600</article-id><article-id pub-id-type="doi">10.1111/irv.12713</article-id><article-id pub-id-type="publisher-id">IRV12713</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Antigenic variants of influenza B viruses isolated in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 influenza seasons</article-title><alt-title alt-title-type="left-running-head">KATO&#x02010;MIYASHITA et al.</alt-title></title-group><contrib-group><contrib id="irv12713-cr-0001" contrib-type="author"><name><surname>Kato&#x02010;Miyashita</surname><given-names>Sari</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0233-8817</contrib-id><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="irv12713-cr-0002" contrib-type="author"><name><surname>Sakai&#x02010;Tagawa</surname><given-names>Yuko</given-names></name><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="irv12713-cr-0003" contrib-type="author"><name><surname>Yamashita</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="irv12713-cr-0004" contrib-type="author"><name><surname>Iwatsuki&#x02010;Horimoto</surname><given-names>Kiyoko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8266-020X</contrib-id><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="irv12713-cr-0005" contrib-type="author"><name><surname>Ito</surname><given-names>Mutsumi</given-names></name><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="irv12713-cr-0006" contrib-type="author"><name><surname>Tokita</surname><given-names>Akifumi</given-names></name><xref ref-type="aff" rid="irv12713-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="irv12713-cr-0007" contrib-type="author"><name><surname>Hagiwara</surname><given-names>Haruhisa</given-names></name><xref ref-type="aff" rid="irv12713-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="irv12713-cr-0008" contrib-type="author"><name><surname>Izumida</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="irv12713-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="irv12713-cr-0009" contrib-type="author"><name><surname>Nishino</surname><given-names>Tamon</given-names></name><xref ref-type="aff" rid="irv12713-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="irv12713-cr-0010" contrib-type="author"><name><surname>Wada</surname><given-names>Noriyuki</given-names></name><xref ref-type="aff" rid="irv12713-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="irv12713-cr-0011" contrib-type="author"><name><surname>Koga</surname><given-names>Michiko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3122-9735</contrib-id><xref ref-type="aff" rid="irv12713-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="irv12713-cr-0012" contrib-type="author"><name><surname>Adachi</surname><given-names>Eisuke</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1623-873X</contrib-id><xref ref-type="aff" rid="irv12713-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="irv12713-cr-0013" contrib-type="author"><name><surname>Jubishi</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="irv12713-cr-0014" contrib-type="author"><name><surname>Yotsuyanagi</surname><given-names>Hiroshi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7882-5262</contrib-id><xref ref-type="aff" rid="irv12713-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="irv12713-cr-0015" contrib-type="author" corresp="yes"><name><surname>Kawaoka</surname><given-names>Yoshihiro</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5061-8296</contrib-id><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0011">
<sup>11</sup>
</xref><xref ref-type="aff" rid="irv12713-aff-0012">
<sup>12</sup>
</xref><address><email>yoshihiro.kawaoka@wisc.edu</email></address></contrib><contrib id="irv12713-cr-0016" contrib-type="author" corresp="yes"><name><surname>Imai</surname><given-names>Masaki</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6988-1975</contrib-id><xref ref-type="aff" rid="irv12713-aff-0001">
<sup>1</sup>
</xref><address><email>mimai@ims.u-tokyo.ac.jp</email></address></contrib></contrib-group><aff id="irv12713-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Division of Virology</named-content>
<named-content content-type="organisation-division">Department of Microbiology and Immunology</named-content>
<named-content content-type="organisation-division">Institute of Medical Science</named-content>
<institution>University of Tokyo</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0002">
<label><sup>2</sup></label>
<institution>Clinic Bambini</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0003">
<label><sup>3</sup></label>
<institution>Members of the Tokyo Pediatric Association Public Health Committee</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0004">
<label><sup>4</sup></label>
<institution>Hagiwara Clinic</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0005">
<label><sup>5</sup></label>
<institution>Akebonocho Clinic</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0006">
<label><sup>6</sup></label>
<institution>Alpaca Kids Ent Clinic</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0007">
<label><sup>7</sup></label>
<institution>Wada Pediatric Clinic</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0008">
<label><sup>8</sup></label>
<named-content content-type="organisation-division">Division of Infectious Diseases</named-content>
<named-content content-type="organisation-division">Advanced Clinical Research Center</named-content>
<named-content content-type="organisation-division">Institute of Medical Science</named-content>
<institution>University of Tokyo</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">Department of Infectious Diseases and Applied Immunology</named-content>
<named-content content-type="organisation-division">IMSUT Hospital of the Institute of Medical Science</named-content>
<institution>University of Tokyo</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0010">
<label><sup>10</sup></label>
<institution>Nezu Clinic</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="irv12713-aff-0011">
<label><sup>11</sup></label>
<named-content content-type="organisation-division">Department of Pathobiological Sciences</named-content>
<named-content content-type="organisation-division">School of Veterinary Medicine</named-content>
<named-content content-type="organisation-division">Influenza Research Institute</named-content>
<institution>University of Wisconsin</institution>
<city>Madison</city>
<named-content content-type="country-part">WI</named-content>
<country country="US">USA</country>
</aff><aff id="irv12713-aff-0012">
<label><sup>12</sup></label>
<named-content content-type="organisation-division">Department of Special Pathogens</named-content>
<named-content content-type="organisation-division">International Research Center for Infectious Diseases</named-content>
<named-content content-type="organisation-division">Institute of Medical Science</named-content>
<institution>University of Tokyo</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Yoshihiro Kawaoka and Masaki Imai, Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108&#x02010;8639, Japan.<break/>
Emails: <email>yoshihiro.kawaoka@wisc.edu</email> (Y. K.); <email>mimai@ims.u-tokyo.ac.jp</email> (M. I.)<break/></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2020</year></pub-date><volume>14</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/irv.v14.3</issue-id><fpage>311</fpage><lpage>319</lpage><history><date date-type="received"><day>21</day><month>6</month><year>2019</year></date><date date-type="rev-recd"><day>11</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 The Authors. <italic>Influenza and Other Respiratory Viruses</italic> Published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:IRV-14-311.pdf"/><abstract id="irv12713-abs-0001"><title>Abstract</title><sec id="irv12713-sec-0001"><title>Background</title><p>Here, we genetically and antigenically analyzed influenza B viruses (IBVs) isolated in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 influenza seasons.</p></sec><sec id="irv12713-sec-0002"><title>Methods</title><p>A total of 68 IBVs (61 B/Yamagata/16/88&#x02010;like [B/Yamagata]&#x02010;lineage and 7 B/Victoria/2/87&#x02010;like [B/Victoria]&#x02010;lineage) were antigenically and genetically characterized by using hemagglutination inhibition (HI) assays and phylogenetic analysis, respectively. The susceptibility of IBVs to neuraminidase (NA) inhibitors was assessed by using a fluorescence&#x02010;based NA inhibition assay.</p></sec><sec id="irv12713-sec-0003"><title>Results</title><p>All 61 B/Yamagata&#x02010;lineage isolates were genetically closely related to B/Phuket/3073/2013, the vaccine strain for these two seasons. Eleven B/Yamagata&#x02010;lineage isolates tested were antigenically similar to B/Phuket/3073/2013 by the HI test. Seven B/Victoria&#x02010;lineage isolates were genetically closely related to B/Texas/02/2013, the WHO&#x02010;recommended vaccine strain for the 2017&#x02010;2018 season; however, they were antigenically distinct from B/Texas/02/2013 with an eightfold or 16&#x02010;fold difference in HI titer. Of these 7 isolates, 4 possessed a two&#x02010;amino&#x02010;acid deletion at positions 162 and 163 in hemagglutinin (HA) and the other 3 had a three&#x02010;amino&#x02010;acid deletion at positions 162&#x02010;164 in HA. Importantly, the variants with the three&#x02010;amino&#x02010;acid deletion appeared to be antigenically different from the B/Colorado/06/2017 virus with the two&#x02010;amino&#x02010;acid deletion, the vaccine strain for the 2018&#x02010;2019 season with a fourfold or eightfold difference in HI titer. One B/Yamagata&#x02010;lineage isolate carrying a G407S mutation in its NA showed a marked reduction in susceptibility to zanamivir, peramivir, and laninamivir.</p></sec><sec id="irv12713-sec-0004"><title>Conclusions</title><p>These results highlight the need for continued monitoring for the prevalence of the antigenic variant with the three&#x02010;amino&#x02010;acid deletion and the variant with reduced NA inhibitor susceptibility.</p></sec></abstract><kwd-group><kwd id="irv12713-kwd-0001">antigenicity</kwd><kwd id="irv12713-kwd-0002">hemagglutinin</kwd><kwd id="irv12713-kwd-0003">influenza B virus</kwd><kwd id="irv12713-kwd-0004">Japan</kwd><kwd id="irv12713-kwd-0005">neuraminidase inhibitors</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Leading Advanced Projects for medical innovation (LEAP) from the Japan Agency for Medical Research and Development (AMED)</funding-source><award-id>JP18am001007</award-id></award-group><award-group id="funding-0002"><funding-source>Grants&#x02010;in&#x02010;Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan</funding-source><award-id>16H06429</award-id><award-id>16H06434</award-id><award-id>16K21723</award-id></award-group><award-group id="funding-0003"><funding-source>Japan Initiative for Global Research Network on Infectious Diseases (J&#x02010;GRID) from AMED</funding-source><award-id>JP19fm0108006</award-id></award-group><award-group id="funding-0004"><funding-source>NIAID&#x02010;funded Center for Research on Influenza Pathogenesis</funding-source><award-id>HHSN272201400008C</award-id></award-group><award-group id="funding-0005"><funding-source>Research Program on Emerging and Re&#x02010;emerging Infectious Diseases from AMED</funding-source><award-id>JP19fk0108031</award-id><award-id>JP19fk0108056</award-id><award-id>JP19fk0108066</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="9"/><word-count count="5517"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.1 mode:remove_FC converted:24.04.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="irv12713-cit-1001">
<string-name>
<surname>Kato&#x02010;Miyashita</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sakai&#x02010;Tagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yamashita</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Antigenic variants of influenza B viruses isolated in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 influenza seasons</article-title>. <source xml:lang="en">Influenza Other Respi Viruses</source>. <year>2020</year>;<volume>14</volume>:<fpage>311</fpage>&#x02013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12713</pub-id>
</mixed-citation>
</p><fn-group id="irv12713-ntgp-0001"><fn id="irv12713-note-0001"><p>The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12713</p></fn></fn-group></notes></front><body id="irv12713-body-0001"><sec id="irv12713-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Influenza is an acute respiratory infectious disease caused by influenza A and B viruses. Currently, two subtypes of influenza A viruses (A/H1N1 and A/H3N2) and two lineages of influenza B viruses (B/Victoria/2/87&#x02010;like [B/Victoria]&#x02010; and B/Yamagata/16/88&#x02010;like [B/Yamagata]&#x02010;lineage) are cocirculating in the human population and cause epidemics of seasonal influenza. Globally, each year, an estimated 5%&#x02010;10% of adults and 20%&#x02010;30% of children are infected with seasonal influenza viruses, causing 3&#x02010;5 million cases of severe illness,<xref rid="irv12713-bib-0001" ref-type="ref">1</xref> and an estimated 290&#x000a0;000&#x02010;650&#x000a0;000 influenza&#x02010;related deaths.<xref rid="irv12713-bib-0002" ref-type="ref">2</xref> Therefore, seasonal influenza is associated with significant morbidity and mortality worldwide.</p><p>The influenza A and B viruses possess two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). HA is the major antigen, which elicits the production of neutralizing antibodies by the host after infection or vaccination. The accumulation of point mutations in the antigenic sites of HA enables viruses to evade host immune responses induced by prior infections or vaccinations, resulting in the emergence of new antigenic variants with epidemic potential.<xref rid="irv12713-bib-0003" ref-type="ref">3</xref>, <xref rid="irv12713-bib-0004" ref-type="ref">4</xref> Anti&#x02010;influenza drugs that inhibit the enzymatic activity of NA are available for the treatment and prophylaxis of influenza; however, mutations in the NA active site reduce its susceptibility to NA inhibitor drugs, leading to the emergence of drug&#x02010;resistant variants.<xref rid="irv12713-bib-0005" ref-type="ref">5</xref>, <xref rid="irv12713-bib-0006" ref-type="ref">6</xref>
</p><p>During the 2017&#x02010;2018 influenza season, influenza A/H1N1 2009 pandemic (A/H1N1pdm), A/H3N2, and B viruses co&#x02010;circulated in Japan.<xref rid="irv12713-bib-0007" ref-type="ref">7</xref> Notably, in Japan, the influenza B epidemic of this season was larger than that of the previous nine seasons. Here, we examined the genetic and antigenic properties of the influenza B viruses isolated in Japan during the winter season. In addition, we characterized the influenza B viruses isolated in Japan during the 2018&#x02010;2019 season, even though influenza B viruses circulated at a lower level in this season compared with the previous season.</p></sec><sec sec-type="materials-and-methods" id="irv12713-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="irv12713-sec-0007"><label>2.1</label><title>Clinical specimens</title><p>After informed consent was obtained, respiratory specimens were collected from patients with influenza&#x02010;like symptoms who visited clinics in Tokyo, Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 seasons. For pediatric patients, informed consent was obtained from the parents. The specimens were submitted to the Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, the University of Tokyo for virus isolation. The research protocol was approved by the Research Ethics Review Committee of the Institute of Medical Science of the University of Tokyo (approval no. 26&#x02010;42&#x02010;0822). Samples that were influenza B&#x02010;positive by real&#x02010;time RT&#x02010;PCR (see below) were used in this study.</p></sec><sec id="irv12713-sec-0008"><label>2.2</label><title>Cells</title><p>Madin&#x02010;Darby canine kidney (MDCK) and AX4<xref rid="irv12713-bib-0008" ref-type="ref">8</xref> cells were maintained in Eagle's minimal essential media (MEM) containing 5% newborn calf serum (NCS). hCK cells were maintained in the presence of 2&#x000a0;&#x000b5;g/mL puromycin and 10&#x000a0;&#x000b5;g/mL blasticidin in MEM containing 5% NCS.<xref rid="irv12713-bib-0009" ref-type="ref">9</xref> Human embryonic kidney 293T cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. The cells were incubated at 37&#x000b0;C with 5% CO<sub>2</sub> and regularly tested for mycoplasma contamination by using PCR and were confirmed to be mycoplasma&#x02010;free.</p></sec><sec id="irv12713-sec-0009"><label>2.3</label><title>Virus isolation and propagation</title><p>MDCK, AX4, or hCK cells grown in 12&#x02010;well plates were inoculated with 0.1&#x000a0;mL per well of the clinical samples and incubated at 33&#x000b0;C for at least 30&#x000a0;minutes. One milliliter of MEM containing 0.3% bovine serum albumin (BSA) and 1&#x000a0;&#x000b5;g/mL TPCK&#x02010;treated trypsin was then added to cells. The cultures were then incubated for up to 7&#x000a0;days, until cytopathic effects were evident. Cell culture supernatants were harvested, viral RNA was extracted and subjected to RT&#x02010;PCR, and the viral genes were sequenced (see below). Influenza B viruses were propagated in MDCK, AX4, or hCK cells in MEM containing 1&#x000a0;&#x000b5;g of L&#x02010;1&#x02010;Tosylamide<italic>&#x02010;</italic>2<italic>&#x02010;</italic>phenylethyl chloromethyl ketone (TPCK)&#x02010;trypsin/mL at 33&#x000b0;C.</p></sec><sec id="irv12713-sec-0010"><label>2.4</label><title>Reverse genetics</title><p>NA inhibitor&#x02010;sensitive and NA inhibitor&#x02010;resistant control viruses were generated by using a plasmid&#x02010;based reverse genetics system as previously described.<xref rid="irv12713-bib-0010" ref-type="ref">10</xref> In brief, plasmids encoding the complementary DNAs for the eight viral RNA segments under the control of the human RNA polymerase I promoter and the mouse RNA polymerase I terminator (referred to as PolI plasmids), and plasmids for the expression of the viral PB2, PB1, PA, and nucleoprotein proteins derived from influenza B virus strain B/Yamagata/1/73, under the control of the chicken &#x003b2;&#x02010;actin promoter,<xref rid="irv12713-bib-0011" ref-type="ref">11</xref> were transfected into 293T cells with the help of a transfection reagent, Trans&#x02010;IT 293 (Mirus). At 48&#x02010;hours post&#x02010;transfection, culture supernatants were collected and inoculated to MDCK cells for virus propagation. All virus stocks were sequenced to confirm the absence of unwanted mutations.</p></sec><sec id="irv12713-sec-0011"><label>2.5</label><title>Real&#x02010;time RT&#x02010;PCR</title><p>Real&#x02010;time PCR was performed to determine the lineage of the influenza B viruses in the clinical specimens. RNA was extracted from clinical specimens by using the simplyRNA Tissue Kit (Promega) or RNeasy Mini Kit (Qiagen). Amplification and detection by real&#x02010;time PCR were performed with the Applied Biosystems 7900HT Fast Real&#x02010;Time PCR System (Applied Biosystems), the StepOnePlus Real&#x02010;Time PCR System (Applied Biosystems), or the LightCycler 96 System (Roche). RT&#x02010;PCR was carried out using the QuantiTect multiplex RT&#x02010;PCR kit (Qiagen) or QuantiTect Probe RT&#x02010;PCR Kit (Qiagen). The probes were designed to target the HA genes of B/Yamagata&#x02010; or B/Victoria&#x02010;lineage viruses. The probes contained oligonucleotides with the 6&#x02010;carboxyfluorescein (FAM) or the hexacholoro&#x02010;6&#x02010;carboxyfluorescein (HEX) reporter dye at the 5&#x02032; end and the Black Hole Quencher&#x02010;1 (BHQ&#x02010;1) or 6&#x02010;carboxytetramethylrhodamine (TAMRA) quencher dye at the 3&#x02032; end. A list of the primers and probes used is provided in Table <xref rid="irv12713-sup-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="irv12713-sec-0012"><label>2.6</label><title>RT&#x02010;PCR and sequencing of viral genes</title><p>Viral RNA was extracted from infected cell culture supernatant by using the QIAmp Viral RNA Mini Kit (Qiagen) and reverse&#x02010;transcribed to cDNA by using Superscript III reverse transcriptase (Thermo Fisher Scientific) and the Uni9/FluB1 primer.<xref rid="irv12713-bib-0012" ref-type="ref">12</xref> PCR was performed with primers specific for the HA or NA genes of influenza B virus. The PCR products were purified and directly sequenced by using BigDye Terminator version 3.1 Cycle Sequencing Kits (Thermo Fisher Scientific), and were then analyzed on an ABI Prism 3130xl Genetic Analyzer (Thermo Fisher Scientific). A list of the primers and probes used is provided in Table <xref rid="irv12713-sup-0001" ref-type="supplementary-material">S1</xref>. The nucleotide sequences obtained in this study were submitted to GISAID's EpiFlu&#x02122; Database and assigned accession numbers as documented in Table <xref rid="irv12713-sup-0001" ref-type="supplementary-material">S2</xref>.</p></sec><sec id="irv12713-sec-0013"><label>2.7</label><title>Phylogenic analysis</title><p>Nucleotide sequences of the HA genes of influenza B viruses were aligned using <sc>mega</sc> version 7.0.26.<xref rid="irv12713-bib-0013" ref-type="ref">13</xref> The phylogenic tree of the HA nucleotide sequences was built in maximum&#x02010;likelihood method with 1000 bootstrap replicates using <sc>mega</sc> version 7.0.26.<xref rid="irv12713-bib-0013" ref-type="ref">13</xref>
</p></sec><sec id="irv12713-sec-0014"><label>2.8</label><title>Experimental infection of ferrets</title><p>Six&#x02010; to seven&#x02010;month&#x02010;old female ferrets (Wuxi Sangosho Biotechnology Co., Ltd.) were used in this study. Ferrets were anesthetized intramuscularly with ketamine and xylazine (5&#x02010;30&#x000a0;mg and 0.2&#x02010;6&#x000a0;mg/kg of body weight, respectively) and inoculated intranasally with 10<sup>6</sup> PFU (0.5&#x000a0;mL) of B/Yokohama/5/2004, B/Brisbane/60/2008, B/Wisconsin/01/2010, B/Massachusetts/02/2012, B/Phuket/3073/2013, B/Texas/02/2013, or B/Colorado/06/2017. These ferrets did not receive a booster immunization. Serum samples were collected and subjected to the hemagglutination inhibition (HI) assay. All experiments with ferrets were performed in accordance with the University of Tokyo's Regulations for Animal Care and Use and were approved by the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo.</p></sec><sec id="irv12713-sec-0015"><label>2.9</label><title>HI assay</title><p>Ferret sera were treated with receptor&#x02010;destroying enzyme (RDE II; Denka Seiken Co., Ltd) at 37&#x000b0;C for 20&#x000a0;hours, followed by RDE inactivation at 56&#x000b0;C for 30&#x02010;60&#x000a0;minutes. The treated sera were serially diluted twofold with PBS in 96&#x02010;well U&#x02010;bottom microtiter plates and mixed with the amount of virus equivalent to four hemagglutination units, followed by incubation at room temperature (25&#x000b0;C) for 60&#x000a0;minutes. After addition of 50&#x000a0;&#x000b5;L of 0.5% chicken red blood cells, the mixtures were gently mixed and incubated at 4&#x000b0;C for a further 45&#x000a0;minutes. HI titers are expressed as the inverse of the highest antibody dilution that inhibited hemagglutination.</p></sec><sec id="irv12713-sec-0016"><label>2.10</label><title>NA inhibition assay</title><p>Oseltamivir carboxylate, peramivir, and laninamivir were kindly provided by Daiichi Sankyo Inc, Tokyo, Japan. Zanamivir was obtained from GlaxoSmithKline, London, UK. In vitro NA activity of viruses was determined as described previously.<xref rid="irv12713-bib-0014" ref-type="ref">14</xref>, <xref rid="irv12713-bib-0015" ref-type="ref">15</xref> Briefly, 2&#x02032;&#x02010;(4&#x02010;methylumbelliferyl)&#x02010;&#x003b1;&#x02010;D&#x02010;N&#x02010;acetylneuraminic acid (MUNANA; Sigma, St Louis, Mo) at a final concentration of 0.1&#x000a0;mmol/L was used as a fluorescent substrate. Dilutions of viruses containing NA activity equivalent to 800&#x02010;1200 fluorescence units were used in this study. Ten microliters of the diluted viruses and 10&#x000a0;&#x000b5;L of the neuraminidase inhibitor (0.01&#x000a0;nmol/L to 10&#x000a0;&#x000b5;mol/L) in calcium&#x02010;MES buffer (33&#x000a0;mmol/L 2&#x02010;[N&#x02010;morpholino]ethanesulfonic acid, 4&#x000a0;mmol/L CaCl<sub>2</sub>, pH 6.0) were mixed and incubated at 37&#x000b0;C for 30&#x000a0;minutes, followed by the addition of 30&#x000a0;&#x000b5;L of the substrate. The mixtures were further incubated at 37&#x000b0;C for 1&#x000a0;hour, and the reaction was stopped by adding 150&#x000a0;&#x000b5;L of 0.1&#x000a0;mol/L sodium hydroxide in 80% ethanol (pH 10.0). The fluorescence of the solution was measured at an excitation wavelength of 360&#x000a0;nm and an emission wavelength of 465&#x000a0;nm. The relationship between the concentration of inhibitor and the percentage of fluorescence inhibition was determined, and 50% inhibitory concentration (IC<sub>50</sub>) values were obtained by extrapolating those findings. The IC<sub>50</sub> values were calculated according to the IC<sub>50</sub> analysis protocol provided by the Health Protection Agency, London, UK.<xref rid="irv12713-bib-0016" ref-type="ref">16</xref>
</p></sec></sec><sec sec-type="results" id="irv12713-sec-0017"><label>3</label><title>RESULTS</title><sec id="irv12713-sec-0018"><label>3.1</label><title>Detection of influenza B viruses in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 seasons</title><p>During the 2017&#x02010;2018 and 2018&#x02010;2019 seasons, a total of 554 respiratory specimens were collected from patients with an influenza&#x02010;like illness in Tokyo, Japan, and 108 were confirmed to be influenza B virus&#x02010;positive by real&#x02010;time RT&#x02010;PCR using lineage&#x02010;specific primers/probes. Of 97 influenza B virus&#x02010;positive samples collected during the 2017&#x02010;2018 season, 95 (97.9%) belonged to the B/Yamagata&#x02010;lineage and two (2.1%) to the B/Victoria&#x02010;lineage. These results are consistent with the National Institute of Infectious Diseases (NIID) report that influenza B viruses of the B/Yamagata&#x02010; and B/Victoria&#x02010;lineages co&#x02010;circulated in Japan during the winter season with the B/Yamagata&#x02010;lineage predominating.<xref rid="irv12713-bib-0007" ref-type="ref">7</xref> Of 11 influenza B virus&#x02010;positive samples collected during the 2018&#x02010;2019 season, two were of the B/Yamagata&#x02010;linage and nine were of the B/Victoria&#x02010;lineage. All 108 influenza B viruses were isolated from the clinical samples by inoculation to MDCK, AX4, or hCK cells. Of the 108 influenza B isolates, 68 (62 from the 2017&#x02010;2018 season and 6 from the 2018&#x02010;2019 season) were selected for further characterization.</p></sec><sec id="irv12713-sec-0019"><label>3.2</label><title>Antigenic and genetic characterization of influenza B viruses isolated in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 seasons</title><p>Recent B/Yamagata&#x02010;lineage viruses have been classified into two distinct genetic clades based on the phylogenetic characterization of the HA gene: clade 2 and clade 3, represented by the vaccine reference strains B/Massachusetts/2/2012 and B/Wisconsin/01/2010, respectively.<xref rid="irv12713-bib-0017" ref-type="ref">17</xref> In contrast, recent B/Victoria&#x02010;lineage viruses belong to clade 1A, which is represented by the vaccine reference strain B/Brisbane/60/2008. To determine the HA gene clade of the 68 influenza B viruses isolated in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 seasons, we performed phylogenetic analysis of their HA genes together with those of other viruses from the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiFlu database. Since the 2015&#x02010;2016 season, only quadrivalent influenza vaccines containing two influenza A virus strains (A/H1N1pdm and A/H3N2) and two influenza B virus strains (B/Yamagata&#x02010;lineage and B/Victoria&#x02010;lineage viruses) have been used in Japan (Table <xref rid="irv12713-sup-0001" ref-type="supplementary-material">S3</xref>). This analysis showed that all 61 B/Yamagata&#x02010;lineage virus isolates fell into clade 3 along with the vaccine strain B/Phuket/3073/2013, which was used in Japan for the 2017&#x02010;2018 and 2018&#x02010;2019 seasons (Figure <xref rid="irv12713-fig-0001" ref-type="fig">1</xref>A and Table <xref rid="irv12713-sup-0001" ref-type="supplementary-material">S3</xref>). The seven B/Victoria&#x02010;lineage isolates possessed HA genes that belonged to clade 1A along with the vaccine strains B/Texas/02/2013 (B/Brisbane/60/2008&#x02010;like virus) and B/Maryland/15/2016 (B/Colorado/06/2017&#x02010;like virus), which were used in Japan for the 2017&#x02010;2018 and the 2018&#x02010;2019 seasons, respectively (Figure <xref rid="irv12713-fig-0001" ref-type="fig">1</xref>B and Table <xref rid="irv12713-sup-0001" ref-type="supplementary-material">S3</xref>). B/Colorado/06/2017 contains a two&#x02010;amino&#x02010;acid deletion at positions 162 and 163 in its HA. Two isolates of the 2017&#x02010;2018 season and two isolates of the 2018&#x02010;2019 season had this two&#x02010;amino&#x02010;acid deletion. The remaining three isolates of the 2018&#x02010;2019 season harbored a three&#x02010;amino&#x02010;acid deletion at positions 162&#x02010;164 of HA. B/Victoria&#x02010;lineage viruses with the three&#x02010;amino&#x02010;acid deletion fell into two distinct subgroups (Figure <xref rid="irv12713-fig-0001" ref-type="fig">1</xref>B): one subgroup shared an amino acid substitution at position K136E, and the other subgroup had two common amino acid substitutions at I180T and K209N. All three viruses with the three&#x02010;amino&#x02010;acid deletion that were isolated during the 2018&#x02010;2019 season in Japan belonged to the former subgroup.</p><fig fig-type="Figure" xml:lang="en" id="irv12713-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Phylogenic tree of the HA genes of (A) B/Yamagata&#x02010; and (B) B/Victoria&#x02010;lineage viruses isolated in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 influenza seasons. The tree was built using the neighbor&#x02010;joining method with 1000 bootstrap replicates. Bootstrap values&#x000a0;&#x02265;&#x000a0;70 are displayed on the branches. The month during which the clinical specimens were collected is shown after each strain name. The scale bar shows a 1% nucleotide change between close relatives. A and B, Influenza B isolates examined in this study are shown in blue. Vaccine and vaccine&#x02010;related strains are indicated in red. The black circle symbol indicated the viruses that were subjected to the HI assay. B, The &#x00394;162&#x02010;163 and &#x00394;162&#x02010;164 indicate viruses possessing the two&#x02010;amino&#x02010;acid deletion at positions 162 and 163 in HA and viruses possessing the three&#x02010;amino&#x02010;acid deletion at positions 162&#x02010;164 in HA, respectively</p></caption><graphic id="nlm-graphic-1" xlink:href="IRV-14-311-g001"/></fig><p>To elucidate whether influenza B viruses isolated in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 influenza seasons were antigenically related to the vaccine strains used for these two seasons in Japan, we performed an HI assay using post&#x02010;infection ferret antisera raised against cell culture&#x02010;propagated vaccine or vaccine&#x02010;related strains. For the B/Yamagata&#x02010;lineage viruses, all 11 isolates tested, which had amino acid substitutions in the globular head domain of their HA compared with the B/Phuket/3073/2013 virus, were readily recognized by the ferret antisera raised against the cell culture&#x02010;propagated vaccine viruses B/Wisconsin/01/2010 and B/Phuket/3073/2013 at titers within twofold of the homologous titer of these antisera and were less well recognized by the ferret antisera raised against the cell culture&#x02010;propagated vaccine virus B/Massachusetts/2/2012 (titers within twofold or fourfold of the homologous titer) (Table <xref rid="irv12713-tbl-0001" ref-type="table">1</xref>). However, like the clade 3 reference viruses B/Wisconsin/01/2010 and B/Phuket/3073/2013, these 11 isolates were poorly recognized by the ferret antisera raised against cell culture&#x02010;propagated B/Yokohama/5/2004, which is genetically closely related to the vaccine virus B/Florida/4/2006, with titers 16&#x02010; or 32&#x02010;fold lower than the homologous titer. These results indicate that all tested B/Yamagata&#x02010;lineage isolates were antigenically and genetically closely related to the vaccine strains B/Wisconsin/01/2010 and B/Phuket/3073/2013.</p><table-wrap id="irv12713-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Antigenic analysis of B/Yamagata&#x02010;lineage viruses isolated in Japan during the 2017&#x02010;2018 season</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="bottom" colspan="1">Virus</th><th align="left" rowspan="3" valign="bottom" colspan="1">Passage history</th><th align="left" rowspan="3" valign="bottom" colspan="1">Genetic clade</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Hemagglutination inhibition titer</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Ferret antiserum</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">B/Yokohama/5/2004</th><th align="left" valign="bottom" rowspan="1" colspan="1">B/Wisconsin/01/2010</th><th align="left" valign="bottom" rowspan="1" colspan="1">B/Massachusetts/2/2012</th><th align="left" valign="bottom" rowspan="1" colspan="1">B/Phuket/3073/2013</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Reference viruses</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Yokohama/5/2004</td><td align="left" rowspan="1" colspan="1">AX4&#x02010;X<xref ref-type="fn" rid="irv12713-note-0003">a</xref>&#x000a0;+&#x000a0;MDCK2</td><td align="char" char="." rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>1280</bold></underline>
</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Wisconsin/01/2010</td><td align="left" rowspan="1" colspan="1">MDCK5</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>640</bold></underline>
</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Massachusetts/2/2012</td><td align="left" rowspan="1" colspan="1">MDCK6</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>640</bold></underline>
</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Phuket/3073/2013</td><td align="left" rowspan="1" colspan="1">MDCK5</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>320</bold></underline>
</td></tr><tr><td align="left" colspan="7" rowspan="1">Test viruses</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;AC034/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;AC035/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;GR026/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;GR045/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;GR052/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">40</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;HP063/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;HP067/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;HP068/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;NZ002/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;LK001/2018</td><td align="left" rowspan="1" colspan="1">AX4&#x02010;1&#x000a0;+&#x000a0;MDCK1</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;WD010/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr></tbody></table><table-wrap-foot id="irv12713-ntgp-0002"><title>Note</title><fn id="irv12713-note-0002"><p>Homologous titers are underlined and bolded.</p></fn><fn id="irv12713-note-0003"><label>a</label><p>X, unknown passage number.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>For B/Victoria&#x02010;lineage viruses, all 7 isolates were subjected to an HI assay. All 7 of the tested isolates were poorly recognized by the ferret antiserum raised against the cell culture&#x02010;propagated vaccine strain B/Texas/02/2013, with titers eightfold or 16&#x02010;fold lower than the homologous titer of this antiserum (Tables <xref rid="irv12713-tbl-0002" ref-type="table">2</xref> and <xref rid="irv12713-tbl-0003" ref-type="table">3</xref>). An antiserum raised against the cell culture&#x02010;propagated vaccine strain B/Brisbane/60/2008 recognized the 7 isolates but at fourfold, eightfold, or 16&#x02010;fold reduced levels compared with the titers of the antiserum for the homologous virus. In contrast, antisera raised against cell culture&#x02010;propagated B/Colorado/06/2017 efficiently inhibited the hemagglutination activity of the four test viruses lacking two amino acids in their HAs, with titers similar to that of the homologous virus<italic>,</italic> consistent with the WHO report.<xref rid="irv12713-bib-0018" ref-type="ref">18</xref> However, the three test viruses carrying the three&#x02010;amino&#x02010;acid deletion were recognized less well by the antiserum against B/Colorado/06/2017 with titers fourfold or eightfold lower than the homologous titer of this antiserum. These results indicate that the four test viruses with the two&#x02010;amino&#x02010;acid deletion are antigenically and genetically closely related to the vaccine virus B/Colorado/06/2017, but the remaining three test viruses with the three&#x02010;amino&#x02010;acid deletion may be antigenically different from the vaccine strain.</p><table-wrap id="irv12713-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Antigenic analysis of B/Victoria&#x02010;lineage viruses isolated in Japan during the 2017&#x02010;2018 season</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="bottom" colspan="1">Virus</th><th align="left" rowspan="3" valign="bottom" colspan="1">Passage history</th><th align="left" rowspan="3" valign="bottom" colspan="1">Genetic clade</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Hemagglutination inhibition titer</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Ferret antiserum</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">B/Brisbane/60/2008</th><th align="left" valign="bottom" rowspan="1" colspan="1">B/Texas/02/2013</th><th align="left" valign="bottom" rowspan="1" colspan="1">B/Colorado/06/2017</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Reference viruses</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Brisbane/60/2008</td><td align="left" rowspan="1" colspan="1">MDCKX<xref ref-type="fn" rid="irv12713-note-0005">a</xref>
</td><td align="left" rowspan="1" colspan="1">1A</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>2560</bold></underline>
</td><td align="char" char="." rowspan="1" colspan="1">1280</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Texas/02/2013</td><td align="left" rowspan="1" colspan="1">MDCK6</td><td align="left" rowspan="1" colspan="1">1A</td><td align="char" char="." rowspan="1" colspan="1">1280</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>1280</bold></underline>
</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Colorado/06/2017</td><td align="left" rowspan="1" colspan="1">MDCK4</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;2 aa)</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>1280</bold></underline>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Test viruses</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;WD028/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;2 aa)</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">1280</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;WD029/2018</td><td align="left" rowspan="1" colspan="1">MDCK2</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;2 aa)</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">1280</td></tr></tbody></table><table-wrap-foot id="irv12713-ntgp-0003"><title>Note</title><fn id="irv12713-note-0004"><p>Homologous titers are underlined and bolded.</p></fn><fn id="irv12713-note-0005"><label>a</label><p>X, unknown passage number.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="irv12713-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Antigenic analysis of B/Victoria&#x02010;lineage viruses isolated in Japan during the 2018&#x02010;2019 season</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="bottom" colspan="1">Virus</th><th align="left" rowspan="3" valign="bottom" colspan="1">Passage history</th><th align="left" rowspan="3" valign="bottom" colspan="1">Genetic clade</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Hemagglutination inhibition titer</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Ferret antiserum</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">B/Brisbane/60/2008</th><th align="left" valign="bottom" rowspan="1" colspan="1">B/Texas/02/2013</th><th align="left" valign="bottom" rowspan="1" colspan="1">B/Colorado/06/2017</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Reference viruses</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Brisbane/60/2008</td><td align="left" rowspan="1" colspan="1">MDCKX<xref ref-type="fn" rid="irv12713-note-0007">a</xref>
</td><td align="left" rowspan="1" colspan="1">1A</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>2560</bold></underline>
</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Texas/02/2013</td><td align="left" rowspan="1" colspan="1">MDCK6</td><td align="left" rowspan="1" colspan="1">1A</td><td align="char" char="." rowspan="1" colspan="1">1280</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>1280</bold></underline>
</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Colorado/06/2017</td><td align="left" rowspan="1" colspan="1">MDCK4</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;2 aa)</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">
<underline underline-style="single"><bold>1280</bold></underline>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Test viruses</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;BB200/2019</td><td align="left" rowspan="1" colspan="1">hCK2</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;2 aa)</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">1280</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;BB207/2019</td><td align="left" rowspan="1" colspan="1">hCK2</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;2 aa)</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">160</td><td align="char" char="." rowspan="1" colspan="1">1280</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;BB241&#x02010;0/2019</td><td align="left" rowspan="1" colspan="1">hCK2</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;3 aa)</td><td align="char" char="." rowspan="1" colspan="1">640</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">320</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;BB248&#x02010;0/2019</td><td align="left" rowspan="1" colspan="1">hCK2</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;3 aa)</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;WD050&#x02010;0/2019</td><td align="left" rowspan="1" colspan="1">hCK2</td><td align="left" rowspan="1" colspan="1">1A (&#x00394;3 aa)</td><td align="char" char="." rowspan="1" colspan="1">320</td><td align="char" char="." rowspan="1" colspan="1">80</td><td align="char" char="." rowspan="1" colspan="1">160</td></tr></tbody></table><table-wrap-foot id="irv12713-ntgp-0004"><title>Note</title><fn id="irv12713-note-0006"><p>Homologous titers are underlined and bolded.</p></fn><fn id="irv12713-note-0007"><label>a</label><p>X, unknown passage number.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="irv12713-sec-0020"><label>3.3</label><title>Antiviral susceptibility</title><p>To monitor the susceptibility of influenza B viruses to NA inhibitors in Japan during the 2017&#x02010;2018 and 2018&#x02010;2019 seasons, the nucleotide sequences of the NA segments of the 68 isolates were determined by means of Sanger sequencing. Sequence analysis revealed no mutations known to confer resistance to NA inhibitors in the influenza B isolates, except for one B/Yamagata&#x02010;lineage isolate (B/Tokyo/UT&#x02010;AC032/2018) that possessed a G407S mutation in its NA.<xref rid="irv12713-bib-0015" ref-type="ref">15</xref> A fluorescence NA inhibition assay with the MUNANA substrate was used to characterize the susceptibility of B/Tokyo/UT&#x02010;AC032/2018 virus to oseltamivir carboxylate, peramivir, zanamivir, and laninamivir (Table <xref rid="irv12713-tbl-0004" ref-type="table">4</xref>). The isolate showed a marked reduction in susceptibility to peramivir, zanamivir, and laninamivir (64&#x02010;, 167&#x02010;, and 204&#x02010;fold increases in IC<sub>50</sub> values, respectively, compared with a drug&#x02010;susceptible control virus, a recombinant virus possessing the HA and NA genes from B/Phuket/3073/2013). This isolate also exhibited moderately reduced susceptibility to oseltamivir carboxylate (eightfold).</p><table-wrap id="irv12713-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Virus sensitivity to NA inhibitors <italic>in vitro</italic>
<xref ref-type="fn" rid="irv12713-note-0008">a</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Virus</th><th align="left" rowspan="2" valign="bottom" colspan="1">NA change</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">IC<sub>50</sub> values (nM) of NA inhibitors (fold differences<xref ref-type="fn" rid="irv12713-note-0009">b</xref>)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Oseltamivir carboxylate<xref ref-type="fn" rid="irv12713-note-0010">c</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">Zanamivir</th><th align="left" valign="bottom" rowspan="1" colspan="1">Peramivir</th><th align="left" valign="bottom" rowspan="1" colspan="1">Laninamivir<xref ref-type="fn" rid="irv12713-note-0011">d</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rPhuket3073/Yamagata<xref ref-type="fn" rid="irv12713-note-0012">e</xref>
</td><td align="left" rowspan="1" colspan="1">wild&#x02010;type</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">64.9&#x000a0;&#x000b1;&#x000a0;11.7 (1.0)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.9&#x000a0;&#x000b1;&#x000a0;1.1 (1.0)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0.5&#x000a0;&#x000b1;&#x000a0;0.1 (1.0)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.5&#x000a0;&#x000b1;&#x000a0;0.1 (1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">rPhuket3073/Yamagata&#x02010;E117A<xref ref-type="fn" rid="irv12713-note-0013">f</xref>
</td><td align="left" rowspan="1" colspan="1">E117A</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">38&#x000a0;075.9&#x000a0;&#x000b1;&#x000a0;7365.0 (586.6)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">164&#x000a0;197.3&#x000a0;&#x000b1;&#x000a0;29&#x000a0;976.2 (27&#x000a0;830.0)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14&#x000a0;959.5&#x000a0;&#x000b1;&#x000a0;296.9 (29&#x000a0;919.0)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">54&#x000a0;022.7&#x000a0;&#x000b1;&#x000a0;4659.7 (21&#x000a0;609.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Tokyo/UT&#x02010;AC032/2018</td><td align="left" rowspan="1" colspan="1">G407S</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">537.2&#x000a0;&#x000b1;&#x000a0;215.7 (8.3)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">986.6&#x000a0;&#x000b1;&#x000a0;507.9 (167.2)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">32.1&#x000a0;&#x000b1;&#x000a0;12.9 (64.2)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">510.1&#x000a0;&#x000b1;&#x000a0;244.4 (204.0)</td></tr></tbody></table><table-wrap-foot id="irv12713-ntgp-0005"><fn id="irv12713-note-0008"><label>a</label><p>IC<sub>50</sub> values were determined by using an NA&#x02010;Fluor Influenza Neuraminidase Assay Kit. Average IC<sub>50</sub> values and standard deviations were calculated from three independent assays performed in duplicate.</p></fn><fn id="irv12713-note-0009"><label>b</label><p>Compared with IC<sub>50</sub> values obtained with the sensitive control rPhuket3073/Yamagata.</p></fn><fn id="irv12713-note-0010"><label>c</label><p>Oseltamivir carboxylate is the active form of oseltamivir.</p></fn><fn id="irv12713-note-0011"><label>d</label><p>Laninamivir is the active form of laninamivir octanoate.</p></fn><fn id="irv12713-note-0012"><label>e</label><p>A recombinant virus possessing the HA and NA genes from B/Phuket/3073/2013 and the remaining genes from B/Yamagata/1/73 virus.</p></fn><fn id="irv12713-note-0013"><label>f</label><p>A recombinant Phuket3073/Yamagata virus with an E117A mutation in its NA.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec sec-type="discussion" id="irv12713-sec-0021"><label>4</label><title>DISCUSSION</title><p>Most of the B/Victoria&#x02010;lineage viruses that were detected worldwide during the eight influenza seasons that followed the 2009&#x02010;2010 season were antigenically closely related to the vaccine strain B/Brisbane/60/2008.<xref rid="irv12713-bib-0019" ref-type="ref">19</xref> In this study, during the 2017&#x02010;2018 and/or 2018&#x02010;2019 seasons in Japan, we detected B/Victoria&#x02010;lineage viruses with a deletion of two or three amino acids at positions 162 and 163 or 162&#x02010;164 in HA, respectively, which are antigenically distinct from the vaccine strain. Antigenic variants possessing the two&#x02010;amino&#x02010;acid deletion were isolated in the United States during the 2016&#x02010;2017 season,<xref rid="irv12713-bib-0020" ref-type="ref">20</xref> whereas variants with the three&#x02010;amino&#x02010;acid deletion were isolated in China and Hong Kong during the 2017&#x02010;2018 season.<xref rid="irv12713-bib-0021" ref-type="ref">21</xref> Subsequently, these antigenic variants have been reported in many countries.<xref rid="irv12713-bib-0018" ref-type="ref">18</xref>, <xref rid="irv12713-bib-0022" ref-type="ref">22</xref> The WHO recommended the B/Colorado/06/2017&#x02010;like virus with the two&#x02010;amino&#x02010;acid deletion for the 2019&#x02010;2020 northern hemisphere influenza vaccine.<xref rid="irv12713-bib-0018" ref-type="ref">18</xref> Our antigenic analyses with post&#x02010;infection ferret sera showed that all tested B/Victoria&#x02010;lineage viruses with the three&#x02010;amino&#x02010;acid deletion were inhibited less well by the antiserum raised against B/Colorado/06/2017 than viruses that possess the two&#x02010;amino&#x02010;acid deletion (Table <xref rid="irv12713-tbl-0003" ref-type="table">3</xref>), consistent with the WHO report.<xref rid="irv12713-bib-0018" ref-type="ref">18</xref> These findings suggest that contemporary B/Victoria&#x02010;lineage viruses with the three&#x02010;amino&#x02010;acid deletion may be antigenically distinguishable from viruses with the two&#x02010;amino&#x02010;acid deletion. Importantly, an increasing proportion of a variant with the three&#x02010;amino&#x02010;acid deletion was reported in many countries during the 2018&#x02010;2019 season.<xref rid="irv12713-bib-0018" ref-type="ref">18</xref> Therefore, continued monitoring for the prevalence of B/Victoria&#x02010;lineage viruses with the three&#x02010;amino&#x02010;acid deletion is important.</p><p>Influenza B viruses carrying the G407S mutation in their NA, which confers reduced susceptibility to NA inhibitors, were sporadically detected in Japan during the 2004&#x02010;2005 season<xref rid="irv12713-bib-0015" ref-type="ref">15</xref> and in Australia and the United States during the 2015&#x02010;2016 season.<xref rid="irv12713-bib-0023" ref-type="ref">23</xref> In this study, we also detected an influenza B virus with the NA&#x02010;G407S mutation during the 2017&#x02010;2018 season in Japan (Table <xref rid="irv12713-tbl-0004" ref-type="table">4</xref>). This virus (B/Tokyo/UT&#x02010;AC032/2018) was isolated from a specimen collected from an adult patient (a 41&#x02010;year&#x02010;old female) prior to drug treatment. Although it is unclear whether the patient had contact with an influenza patient who was treated with NA inhibitors, it is possible that this variant may be transmissible from person to person. Further investigations are required to determine whether this NA&#x02010;G407S mutation affects the transmissibility of influenza B viruses.</p><p>This virological surveillance study may have been limited by the fact that samples were collected in a limited area in Japan and by the relatively small number of influenza B isolates. Nevertheless, such monitoring of the most recent circulating strains contributes to the early detection of new antigenic variants and drug&#x02010;resistant viruses.</p></sec><sec sec-type="COI-statement" id="irv12713-sec-0023"><title>CONFLICT OF INTEREST</title><p>SK&#x02010;M., YS&#x02010;T., KI&#x02010;H., M.Ito., AT, HH, NI, TN, NW, MK, EA, DJ, HY, and M. Imai have no competing interests. MY has received speaker's honoraria from Daiichi Sankyo Co., Ltd. YK has received speaker's honoraria from Toyama Chemical and Astellas, Inc; grant support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Shionogi &#x00026; Co., Ltd., and Kyoritsu Seiyaku; and is a founder of FluGen.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="irv12713-sup-0001"><caption><p>&#x000a0;</p></caption><media xlink:href="IRV-14-311-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="irv12713-sec-0022"><title>ACKNOWLEDGEMENTS</title><p>We thank the Global Initiative on Sharing Avian Influenza Data (GISAID) for sharing the influenza virus sequence data used in this study. We also thank Daiichi Sankyo Inc for providing oseltamivir carboxylate, peramivir, and laminamivir, Chiharu Kawakami for providing B/Yokohama/5/2004, and Shinji Watanabe for providing the vaccine reference strains. In addition, we thank Susan Watson for scientific editing, Akari Fukuda for technical assistance and Kosuke Takada, Taiki Hamabata, Michiko Ujie and Tokiko Watanabe for help in generating antisera in ferrets. This research was supported by Leading Advanced Projects for medical innovation (LEAP) from the Japan Agency for Medical Research and Development (AMED) (JP18am001007), by Grants&#x02010;in&#x02010;Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) of Japan (Nos. 16H06429, 16K21723, and 16H06434), by the Japan Initiative for Global Research Network on Infectious Diseases (J&#x02010;GRID) from AMED (JP19fm0108006), by a Research Program on Emerging and Re&#x02010;emerging Infectious Diseases from AMED (JP19fk0108031, JP19fk0108056, and JP19fk0108066), and by the NIAID&#x02010;funded Center for Research on Influenza Pathogenesis (CRIP, HHSN272201400008C).</p></ack><ref-list content-type="cited-references" id="irv12713-bibl-0001"><title>REFERENCES</title><ref id="irv12713-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0001">
<collab collab-type="authors">WHO</collab>
. <article-title>Influenza</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/biologicals/vaccines/influenza/en/">https://www.who.int/biologicals/vaccines/influenza/en/</ext-link>. Accessed 27 May 2019.</mixed-citation></ref><ref id="irv12713-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="irv12713-cit-0002">
<string-name>
<surname>Iuliano</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Roguski</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>HH</given-names>
</string-name>, et al. <article-title>Estimates of global seasonal influenza&#x02010;associated respiratory mortality: a modelling study</article-title>. <source xml:lang="en">Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>1285</fpage>&#x02010;<lpage>1300</lpage>.<pub-id pub-id-type="pmid">29248255</pub-id></mixed-citation></ref><ref id="irv12713-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="irv12713-cit-0003">
<string-name>
<surname>Hay</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Gregory</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Douglas</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>PL</given-names>
</string-name>. <article-title>The evolution of human influenza viruses</article-title>. <source xml:lang="en">Philos Trans R Soc B Biol Sci</source>. <year>2001</year>;<volume>356</volume>:<fpage>1861</fpage>&#x02010;<lpage>1870</lpage>.</mixed-citation></ref><ref id="irv12713-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="irv12713-cit-0004">
<string-name>
<surname>Carrat</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Flahault</surname>
<given-names>A</given-names>
</string-name>. <article-title>Influenza vaccine: the challenge of antigenic drift</article-title>. <source xml:lang="en">Vaccine</source>. <year>2007</year>;<volume>25</volume>:<fpage>6852</fpage>&#x02010;<lpage>6862</lpage>.<pub-id pub-id-type="pmid">17719149</pub-id></mixed-citation></ref><ref id="irv12713-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="irv12713-cit-0005">
<string-name>
<surname>Burnham</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Baranovich</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Govorkova</surname>
<given-names>EA</given-names>
</string-name>. <article-title>Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2013</year>;<volume>100</volume>:<fpage>520</fpage>&#x02010;<lpage>534</lpage>.<pub-id pub-id-type="pmid">24013000</pub-id></mixed-citation></ref><ref id="irv12713-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="irv12713-cit-0006">
<string-name>
<surname>Mckimm&#x02010;Breschkin</surname>
<given-names>JL</given-names>
</string-name>. <article-title>Influenza neuraminidase inhibitors: Antiviral action and mechanisms of resistance</article-title>. <source xml:lang="en">Influenza Other Respi Viruses</source>. <year>2013</year>;<volume>7</volume>:<fpage>25</fpage>&#x02010;<lpage>36</lpage>.</mixed-citation></ref><ref id="irv12713-bib-0007"><label>7</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0007">
<collab collab-type="authors">National Institute of Infectious Diseases in Japan</collab>
. <article-title>Infectious Agents Surveillance Report</article-title>. <ext-link ext-link-type="uri" xlink:href="https://nesid4g.mhlw.go.jp/Byogentai/Pdf/data95j.pdf">https://nesid4g.mhlw.go.jp/Byogentai/Pdf/data95j.pdf</ext-link>. Accessed 27 May 2019.</mixed-citation></ref><ref id="irv12713-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="irv12713-cit-0008">
<string-name>
<surname>Hatakeyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sakai&#x02010;Tagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kiso</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Enhanced expression of an &#x003b1;2,6&#x02010;linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor</article-title>. <source xml:lang="en">J Clin Microbiol</source>. <year>2005</year>;<volume>43</volume>:<fpage>4139</fpage>&#x02010;<lpage>4146</lpage>.<pub-id pub-id-type="pmid">16081961</pub-id></mixed-citation></ref><ref id="irv12713-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="irv12713-cit-0009">
<string-name>
<surname>Takada</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kawakami</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses</article-title>. <source xml:lang="en">Nat Microbiol</source>. <year>2019</year>;<volume>4</volume>(<issue>8</issue>):<fpage>1268</fpage>&#x02010;<lpage>1273</lpage>.<pub-id pub-id-type="pmid">31036910</pub-id></mixed-citation></ref><ref id="irv12713-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="irv12713-cit-0010">
<string-name>
<surname>Neumann</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Generation of influenza A viruses entirely from cloned cDNAs</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>. <year>1999</year>;<volume>96</volume>(<issue>16</issue>):<fpage>9345</fpage>&#x02010;<lpage>9350</lpage>.<pub-id pub-id-type="pmid">10430945</pub-id></mixed-citation></ref><ref id="irv12713-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="irv12713-cit-0011">
<string-name>
<surname>Niwa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yamamura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miyazaki</surname>
<given-names>J</given-names>
</string-name>. <article-title>Efficient selection for high&#x02010;expression transfectants with a novel eukaryotic vector (Recombinant DNA; B&#x02010;actin promoter; bovine papilloma virus; transfection; interleukin&#x02010;2; G418 selection; copy number)</article-title>. <source xml:lang="en">Gene</source>. <year>1991</year>;<volume>108</volume>:<fpage>193</fpage>&#x02010;<lpage>199</lpage>.<pub-id pub-id-type="pmid">1660837</pub-id></mixed-citation></ref><ref id="irv12713-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="irv12713-cit-0012">
<string-name>
<surname>Zhou</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics</article-title>. <source xml:lang="en">J Clin Microbiol</source>. <year>2014</year>;<volume>52</volume>:<fpage>1330</fpage>&#x02010;<lpage>1337</lpage>.<pub-id pub-id-type="pmid">24501036</pub-id></mixed-citation></ref><ref id="irv12713-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="irv12713-cit-0013">
<string-name>
<surname>Kumar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stecher</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tamura</surname>
<given-names>K</given-names>
</string-name>. <article-title>MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets</article-title>. <source xml:lang="en">Mol Biol Evol</source>. <year>2016</year>;<volume>33</volume>:<fpage>1870</fpage>&#x02010;<lpage>1874</lpage>.<pub-id pub-id-type="pmid">27004904</pub-id></mixed-citation></ref><ref id="irv12713-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="irv12713-cit-0014">
<string-name>
<surname>Kiso</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iwatsuki&#x02010;Horimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yamayoshi</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Emergence of oseltamivir&#x02010;resistant H7N9 influenza viruses in immunosuppressed cynomolgus macaques</article-title>. <source xml:lang="en">J Infect Dis</source>. <year>2017</year>;<volume>216</volume>:<fpage>582</fpage>&#x02010;<lpage>593</lpage>.<pub-id pub-id-type="pmid">28931216</pub-id></mixed-citation></ref><ref id="irv12713-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="irv12713-cit-0015">
<string-name>
<surname>Hatakeyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sugaya</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors</article-title>. <source xml:lang="en">JAMA</source>. <year>2007</year>;<volume>297</volume>:<fpage>4</fpage>&#x02010;<lpage>6</lpage>.</mixed-citation></ref><ref id="irv12713-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0016">
<collab collab-type="authors">Isirv Antiviral Group</collab>
. <article-title>Neuraminidase Inhibition Assay (IC50)</article-title>. <ext-link ext-link-type="uri" xlink:href="https://isirv.org/site/index.php/methodology/nai-assay-ic50">https://isirv.org/site/index.php/methodology/nai-assay-ic50</ext-link>. Accessed 15 September 2019.</mixed-citation></ref><ref id="irv12713-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0017">
<collab collab-type="authors">WHO</collab>
. <article-title>Weekly epidemiological record</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/wer/2014/wer8941.pdf">https://www.who.int/wer/2014/wer8941.pdf</ext-link>. Accessed 12 September 2019.</mixed-citation></ref><ref id="irv12713-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0018">
<collab collab-type="authors">WHO</collab>
. <article-title>Weekly epidemiological record</article-title>. <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/311440/WER9412.pdf">https://apps.who.int/iris/bitstream/handle/10665/311440/WER9412.pdf</ext-link>. Accessed 24 May 2019.</mixed-citation></ref><ref id="irv12713-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0019">
<collab collab-type="authors">WHO</collab>
. <article-title>WHO recommendations on the composition of influenza virus vaccines</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/vaccines/virus/recommendations/en/">https://www.who.int/influenza/vaccines/virus/recommendations/en/</ext-link>. Accessed 3 June 2019.</mixed-citation></ref><ref id="irv12713-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="irv12713-cit-0020">
<string-name>
<surname>Blanton</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Alabi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mustaquim</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Update: influenza activity in the United States during the 2016&#x02013;17 season and composition of the 2017&#x02013;18 influenza vaccine</article-title>. <source xml:lang="en">MMWR Morb Mortal Wkly Rep</source>. <year>2017</year>;<volume>66</volume>:<fpage>668</fpage>&#x02010;<lpage>676</lpage>.<pub-id pub-id-type="pmid">28662019</pub-id></mixed-citation></ref><ref id="irv12713-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0021">
<collab collab-type="authors">WHO</collab>
. <article-title>Weekly epidemiological record</article-title>. <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/260550/WER9312.pdf">https://apps.who.int/iris/bitstream/handle/10665/260550/WER9312.pdf</ext-link>. Accessed 27 May 2019.</mixed-citation></ref><ref id="irv12713-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="irv12713-cit-0022">
<collab collab-type="authors">WHO</collab>
. <article-title>Recommended composition of influenza virus vaccines for use in the 2019 southern hemisphere influenza season</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/vaccines/virus/recommendations/201809_recommendation.pdf">https://www.who.int/influenza/vaccines/virus/recommendations/201809_recommendation.pdf</ext-link>. Accessed 3 June 2019.</mixed-citation></ref><ref id="irv12713-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="irv12713-cit-0023">
<string-name>
<surname>Gubareva</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Besselaar</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Daniels</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015&#x02013;2016</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2017</year>;<volume>146</volume>:<fpage>12</fpage>&#x02010;<lpage>20</lpage>.<pub-id pub-id-type="pmid">28802866</pub-id></mixed-citation></ref></ref-list></back></article>